JP2013542262A - デキサメタゾン併用療法 - Google Patents

デキサメタゾン併用療法 Download PDF

Info

Publication number
JP2013542262A
JP2013542262A JP2013538921A JP2013538921A JP2013542262A JP 2013542262 A JP2013542262 A JP 2013542262A JP 2013538921 A JP2013538921 A JP 2013538921A JP 2013538921 A JP2013538921 A JP 2013538921A JP 2013542262 A JP2013542262 A JP 2013542262A
Authority
JP
Japan
Prior art keywords
amount
compound
treatment
dexamethasone
multiple myeloma
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
JP2013538921A
Other languages
English (en)
Japanese (ja)
Other versions
JP2013542262A5 (enExample
Inventor
イ、チン
ゼン、ユファン
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
The University of Texas System
Original Assignee
The University of Texas System
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=45094245&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=JP2013542262(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by The University of Texas System filed Critical The University of Texas System
Publication of JP2013542262A publication Critical patent/JP2013542262A/ja
Publication of JP2013542262A5 publication Critical patent/JP2013542262A5/ja
Withdrawn legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
JP2013538921A 2010-11-12 2011-11-11 デキサメタゾン併用療法 Withdrawn JP2013542262A (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US41326010P 2010-11-12 2010-11-12
US61/413,260 2010-11-12
US42008910P 2010-12-06 2010-12-06
US61/420,089 2010-12-06
PCT/US2011/060297 WO2012065021A1 (en) 2010-11-12 2011-11-11 Dexamethasone combination therapy

Publications (2)

Publication Number Publication Date
JP2013542262A true JP2013542262A (ja) 2013-11-21
JP2013542262A5 JP2013542262A5 (enExample) 2014-12-18

Family

ID=45094245

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2013538921A Withdrawn JP2013542262A (ja) 2010-11-12 2011-11-11 デキサメタゾン併用療法

Country Status (11)

Country Link
US (1) US20130310352A1 (enExample)
EP (1) EP2637665B1 (enExample)
JP (1) JP2013542262A (enExample)
KR (1) KR20140009222A (enExample)
CN (1) CN103313714A (enExample)
AU (1) AU2011326394A1 (enExample)
BR (1) BR112013011728A2 (enExample)
CA (1) CA2816601A1 (enExample)
MX (1) MX2013005271A (enExample)
RU (1) RU2013126798A (enExample)
WO (1) WO2012065021A1 (enExample)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10537585B2 (en) 2017-12-18 2020-01-21 Dexcel Pharma Technologies Ltd. Compositions comprising dexamethasone
WO2020168106A1 (en) 2019-02-13 2020-08-20 Notable Labs, Inc. Combinations of agonists of protein kinase c with steroids or retinoic acids for the treatment of cancer
KR20220110243A (ko) * 2019-12-02 2022-08-05 셀진 코포레이션 암의 치료를 위한 요법

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JO2660B1 (en) 2006-01-20 2012-06-17 نوفارتيس ايه جي Pi-3 inhibitors and methods of use

Also Published As

Publication number Publication date
EP2637665A1 (en) 2013-09-18
KR20140009222A (ko) 2014-01-22
BR112013011728A2 (pt) 2016-08-16
US20130310352A1 (en) 2013-11-21
RU2013126798A (ru) 2014-12-20
CN103313714A (zh) 2013-09-18
WO2012065021A1 (en) 2012-05-18
MX2013005271A (es) 2013-09-26
AU2011326394A1 (en) 2013-05-30
CA2816601A1 (en) 2012-05-18
EP2637665B1 (en) 2015-04-08

Similar Documents

Publication Publication Date Title
AU2021225157B2 (en) Combination therapy of tetracyclic quinolone analogs for treating cancer
RU2726367C2 (ru) Фармацевтические комбинации для лечения злокачественной опухоли
JP6626437B2 (ja) ヒストンデアセチラーゼ阻害剤とＨｅｒ２阻害剤またはＰＩ３Ｋ阻害剤のいずれかの組み合わせ
JP2021073314A (ja) ヒストンデアセチラーゼ阻害薬及び免疫調節薬の組み合わせ
JP5876435B2 (ja) 骨髄腫の処置のためのｈｄａｃ阻害剤の使用
KR20170044097A (ko) 히스톤 탈아세틸화효소 저해제에 의한 백혈병의 치료
RU2630975C2 (ru) Режим дозирования pi-3 киназы
JP7406264B2 (ja) 皮膚障害の処置のためのシアノアリール－アニリン化合物
JP7393808B2 (ja) 皮膚障害の処置のためのナフチリジノン－アニリン化合物
JP2011520846A (ja) 多発性骨髄腫の治療
CN118574617A (zh) 使用ptpn11抑制剂和kras g12c抑制剂的组合疗法
AU2006259638A1 (en) Synergistic modulation of FLT3 kinase using a FLT3 inhibitor and a farnesyl transferase inhibitor
CA3227033A1 (en) Compositions for use in treating b-cell malignancies
US20160287553A1 (en) Translation inhibitors in high-dose chemo- and/or high-dose radiotherapy
EP2637665B1 (en) Dexamethasone combination therapy
EP3880207A1 (en) Combination of a mcl-1 inhibitor and midostaurin, uses and pharmaceutical compositions thereof
US20250375468A1 (en) Novel ras inhibitors
RU2754131C1 (ru) Комбинированная терапия ингибитором ezh2
CA3182616A1 (en) Tlr7/8 antagonists and uses thereof
RU2850269C2 (ru) Фармацевтические комбинации для лечения злокачественной опухоли
RU2786570C2 (ru) Комбинированная терапия тетрациклическими аналогами хинолона для лечения рака
HK1261603B (en) Combination therapy of tetracyclic quinolone analogs for treating cancer
HK1261603A1 (en) Combination therapy of tetracyclic quinolone analogs for treating cancer

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20141028

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20141029

A761 Written withdrawal of application

Free format text: JAPANESE INTERMEDIATE CODE: A761

Effective date: 20150511